Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S1473309926002240?dgcid=rss_sd_all
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S1473309926002240?dgcid=rss_sd_all
“Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.” The Lancet Infectious Diseases.
@article{article68738,
title = {Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S1473309926002240?dgcid=rss_sd_all}
}